Article thumbnail

Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens

By Christopher D. O. Cooper, Charles H. Lawrie, Amanda P. Liggins, Graham P. Collins, Christian S. R. Hatton, Karen Pulford and Alison H. Banham


Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL). With notable exceptions such as ALK+ anaplastic large cell lymphoma (ALCL, ALK+), the molecular abnormalities in PTCL remain poorly characterised. We had previously identified circulating antibodies to ALK in patients with ALCL, ALK+. Thus, as a strategy to identify potential antigens associated with the pathogenesis of PTCL, not otherwise specified (PTCL, NOS), we screened a testis cDNA library with sera from four PTCL, NOS patients using the SEREX (serological analysis of recombinant cDNA expression libraries) technique. We identified nine PTCL, NOS-associated antigens whose immunological reactivity was further investigated using sera from 52 B- and T-cell lymphoma patients and 17 normal controls. The centrosomal protein CEP250 was specifically recognised by patients sera and showed increased protein expression in cell lines derived from T-cell versus B-cell malignancies. TCEB3, BECN1, and two previously uncharacterised proteins, c14orf93 and ZBTB44, were preferentially recognised by patients' sera. Transcripts for all nine genes were identified in 39 cancer cell lines and the five genes encoding preferentially lymphoma-recognised antigens were widely expressed in normal tissues and mononuclear cell subsets. In summary, this study identifies novel molecules that are immunologically recognised in vivo by patients with PTCL, NOS. Future studies are needed to determine whether these tumor antigens play a role in the pathogenesis of PTCL

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol,
  2. (2006). Autophagy is induced in CD4+ T cells and important for the growth factor-withdrawal cell death.
  3. (2007). Autophagy suppresses tumor progression by limiting chromosomal instability.
  4. (2006). B and CTL responses to the ALK protein in patients with ALK-positive ALCL.
  5. (2010). Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer Tcell lymphoma, nasal type.
  6. (2006). Born to bind: the BTB protein-protein interaction domain.
  7. (2003). Centrosome aberrations as a possible mechanism for chromosomal instability in nonHodgkin’s lymphoma.
  8. (2009). Centrosome function in cancer: guilty or innocent? Trends Cell Biol.
  9. (2007). Chromosomal instability and supernumerary centrosomes represent precursor defects in a mouse model of T-cell lymphoma.
  10. (2000). Chromosome abnormalities in peripheral T-cell lymphoma.
  11. ConawayRC(1995)Elongin (SIII):amultisubunit regulator of elongation by RNA polymerase II.
  12. (2010). Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
  13. (2008). Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol.
  14. (1997). Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
  15. (2007). Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
  16. (2004). Functional proteomics mapping of a human signaling pathway.
  17. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in nonHodgkin’s lymphoma.
  18. (2007). Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.
  19. (2007). Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.
  20. (2007). Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas.
  21. (2005). Identification of lymphomaassociated antigens using SEREX.
  22. (2000). Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
  23. (2007). Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins.
  24. (2007). Induction of apoptosis and cellular senescence in mice lacking transcription elongation factor,
  25. (2008). Kank proteins: a new family of ankyrin-repeat domain-containing proteins.
  26. (2006). Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.
  27. (2007). MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.
  28. (1989). Molecular cloning. A laboratory manual.
  29. (2007). Oncogenes and tumour suppressors take on centrosomes.
  30. (2003). Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies.
  31. (2001). Pathology and genetics: tumours of haematopoietic and lymphoid tissues.
  32. (2006). Peripheral T-cell lymphoma gene expression profiles.
  33. (1990). Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives).
  34. (1998). Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L.
  35. (2003). Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.
  36. (2009). Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.
  37. (2006). RNA polymerase II bypass of oxidative DNA damage is regulated by transcription elongation factors.
  38. (2005). Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
  39. (2004). SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma.
  40. (2004). Serologic detection of diffuse large B-cell lymphoma-associated antigens.
  41. (2001). Serological detection of cutaneous T-cell lymphoma-associated antigens.
  42. (2005). The biology of human lymphoid malignancies revealed by gene expression profiling.
  43. (2004). The cancer/testis genes: review, standardization, and commentary.
  44. (2000). The centrosomal protein C-Nap1 is required for cell cycle-regulated centrosome cohesion.
  45. (1996). The clinicopathological features of anaplastic large cell lymphomas expressing p80 NPM/ALK.
  46. (2007). The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
  47. (1997). The Non-Hodgkin’s Lymphoma Classification Project
  48. (2007). The role of BTB domain-containing zinc finger proteins in T cell development and function. Immunol Lett 108: 1–9.
  49. (2003). Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity.
  50. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.